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Abstract
Background: Mortality is high in patients with esophageal carcinoma as tumors are rarely detected before the
disease has progressed to an advanced stage. Here, we sought to isolate cell-free DNA released into the plasma of
patients with esophageal carcinoma, to analyze copy number variations of marker genes in the search for early
detection of tumor progression.
Methods: Plasma of 41 patients with esophageal carcinoma was prospectively collected before tumor resection
and chemotherapy. Our dataset resulted heterogeneous for clinical data, resembling the characteristics of the
tumor. DNA from the plasma was extracted to analyze copy number variations of the erbB2 gene using real-time
PCR assays.
Results: The real-time PCR assays for erbB2 gene showed significant (P = 0.001) copy number variations in the
plasma of patients with esophageal carcinoma, as compared to healthy controls with high sensitivity (80%) and
specificity (95%). These variations in erbB2 were negatively correlated to the progression free survival of these
patients (P = 0.03), and revealed a further risk category stratification of patients with low VEGF expression levels.
Conclusion: The copy number variation of erbB2 gene from plasma can be used as prognostic marker for early
detection of patients at risk of worse clinical outcome in esophageal cancer.
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Background
Esophageal carcinoma (EC) is the eighth most common
cancer and the sixth leading cause of cancer-related
death worldwide. In European Union, in 2006, were esti-
mated 25.000 cases per years in men and 8.300 in
w o m e n[ 1 ] .I nI t a l y ,d a t af r o mI t a l i a nA s s o c i a t i o nf o r
Tumors Registry (AIRTIUM) accounts in 2003, 2.195
cases with 40 new cases per years in Naples (see: http://
www.registri-tumori.it/cms/). The mortality associated
with EC is high because tumors are rarely detected
before the disease has progressed to an advanced stage.
Even when the primary tumor is resectable, the overall
5-year survival rate is under 10% [2]. The stage at which
EC is detected is the most important factor in
determining prognosis (classified according to the T, N,
M system). The rate of lymph node metastasis in both
squamous cell carcinoma and adenocarcinoma, the two
main histological types of EC, is related to the depth of
invasion [3-5]. The majority of ECs that present with
symptoms have already invaded the muscularis propria
(T3) and have already spread to local lymph nodes (N1);
this is the reason for the poor prognosis.
New approaches to early detection and monitoring of
the course of therapy would benefit the clinical manage-
ment of patients with EC. Several prognostic factors are
currently accepted for clinical use, such as nodal status
and tumor stage; however, the disease status and clini-
copathological conditions cannot unequivocally identify
which patients are at low or high risk for disease recur-
rence [2,6]. Therefore, there remains the need to iden-
tify better prognostic markers that can be used with
biological fluids [7,8].
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oncogene encodes a transmembrane tyrosine kinase
receptor that has evolved as a major classifier of invasive
breast cancer and a target of therapy for the disease [9].
H o w e v e r ,t h er o l eo ferbB2 in EC is still controversial.
Some studies have seen erbB2 over-expression in 20% to
60% of ECs, with this wide range indicating that the dif-
ferences might depend on tumor stage or histology, or
on the interpretation of the immunohistochemistry
results. Another study underlined the lack of a prognos-
tic impact of erbB2 amplification in primary ECs [10].
An additionally study showed gene-specific quantitative
PCR amplification of the erbB2 gene in tumor cells
from lymph nodes and bone marrow from 98 patients
with EC [11]. In 50% of 17q12.21 gains, the erbB2 gene
was gained in tumor cells from both lymph nodes and
bone marrow. Interestingly, only a gain of erbB2,a n d
not of 17q12.21, was indicative of poor patient survival,
suggesting that erbB2 gains are critical for systemic EC.
While a gain in erbB2 in a single disseminated cancer
cell has been shown to be an important risk factor in
multivariate analysis, erbB2 amplification in primary
tumors was not associated with poor survival both in a
group of patients that were analyzed for disseminated
cancer cells, and in a study cohort comprising twice as
many patients [11]. Furthermore, erbB2 gene amplifica-
tion has been demonstrated in the esophageal adenocar-
cinoma histotype, in 39 patients versus 39 control
samples [12].
The formation of new blood vessels (angiogenesis)
and lymph vessels (lymphangiogenesis) significantly con-
tributes to malignant growth and metastasis of solid
tumors [13-15]. Angiogenesis and lymphangiogenesis
are mediated by distinct cytokines and their receptors.
The best characterized and most specific cytokines are
the vascular endothelial growth factors (VEGF-A, -B,
-C, -D and -E) and their receptors (VEGFR-1, -2 and
-3) [16,17]. Clinicopathological and experimental studies
on VEGF-C/D expression in esophageal squamous cell
specimens and in esophageal adenocarcinoma speci-
mens have been published [18,19]. Studies on esopha-
geal squamous carcinoma have resulted in a relatively
consistent correlation of growth-factor expression to
tumor progression and lymphatic spread. A recent
study reported up-regulation of serum VEGF-C in eso-
phageal squamous cell carcinoma, a finding that paral-
lels VEGF-C expression in tissue specimens [20]. They
also correlated serum levels of VEGF-C with the pre-
sence of lymph node metastasis, and concluded that
VEGF-C up-regulation did not arise from platelets or
white blood cells.
Many studies have indicated that soluble DNA from
tumors can be detected in the serum and plasma of
patients with cancers; alterations in both microsatellites
and amplification of oncogenes corresponding to the
lesions in tumors have been identified in the serum and
plasma of patients with several cancers [21-27]. Analysis
of DNA from plasma represents a non-invasive method
for detection of circulating tumor cells (CTCs) or their
DNA released from the primary tumor into the plasma/
serum [21-26]. However, a question that remains deba-
table is whether this DNA is released from primary dis-
sociating tumor cells or from cells that invade the
blood. CTCs have been shown to be a critical link
between the primary cancers and metastatic disease,
which continues to be the leading cause of death for
most malignancies [28]. A sensitive and specific system
for quantification of CTCs and their free DNA would
thus be a useful diagnostic tool in EC, for monitoring
the dissemination of tumor cells into the peripheral
serum. As copy-number variations (CN) and over-
expression are among the major genomic aberrations in
EC pathogenesis, and as the erbB2 gene has been found
both in circulating tumor cells from lymph nodes and
bone marrow of EC patients, here we studied erbB2 CN
variations in the free DNA from plasma of patients with
EC [29]. We show that sensitive and fast real-time PCR
technology can indeed detect erbB2 CN variations in the
free DNA from plasma of EC patients collected before
tumors resection and chemotherapy. We also show that
erbB2 CN variations correlates to VEGF levels and that
together can be used as predictive markers for worse
clinical outcome.
Methods
Sample collection
The present study included 41 patients (men and
women; aged 52-74 years) with EC, as diagnosed by the
Dipartimento Medico-Chirurgico di Internistica Clinica
eS p e r i m e n t a l e“F. Magrassi e A. Lanzara” SUN,
Seconda Università degli Studi, Naples, Italy. The ethics
committee of the SUN approved this study, and
informed written consent was obtained from all of the
patients before inclusion in the study. The clinicopatho-
logical characteristics of the EC patients are described in
Additional file 1: Supplemental Table S1. Thirty-four
peripheral EDTA blood samples from 34 healthy volun-
teers formed the negative control group. The peripheral
blood of both cases and controls was centrifuged at
2850 × g for 10 min at 4°C, and the supernatant
(plasma) was stored at -80°C until analysis. The time lag
between blood collection and plasma processing was at
most of four hours for both EC patients and healthy
controls.
All of the plasma samples from the patients with EC
included in the present study were collected before sur-
gical tumor resection and before chemotherapy
treatment.
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A total of 500 μL of plasma was treated with 1 mg mL
-1
proteinase K (GIBCO) and 10% SDS (Sigma Aldrich) for
1 h at 65°C. These samples were then heated to 95°C
for 10 min, to inactivate the proteinase K. The DNA in
the samples was then phenol extracted and ethanol pre-
cipitated. After centrifugation at 6000 × g for 15 min at
4°C, the DNA pellets were dissolved in 30 μls t e r i l e
water.
Cloning of the real-time PCR amplification products of
erbB2 and b-actin for copy number analysis
Following PCR amplification, the real-time PCR amplifi-
cation products for erbB2 and b-actin were cloned sepa-
rately into the pcr 2.1 vector, using the original TA
cloning system (Invitrogen). Briefly, fragments of the
erbB2 and b-actin genes were amplified from genomic
DNA of healthy control peripheral blood. The PCR pri-
mers and cycling conditions were the same as those
u s e df o rr e a l - t i m eP C Ro ft h eD N Af r o mt h eE C
patients. After the cloning into the pcr 2.1 vector, the
erbB2 and b-actin plasmids were prepared at a concen-
tration of 100 ng/μl.
Determination of ErbB2 copy number variations
Real-time PCR
Real-time quantitative PCR (Syber Green method) was
performed using standard protocols with an Applied
Biosystems ABI PRISM 7900HT Sequence Detection
system. Briefly, 100 ng DNA was added to 12.5 μlo f
SYBR-green PCR master mix (Applied Biosystems), with
600 nM of each primer, and water to 25 μl. The reac-
tions were amplified with a single step of 2 min at 50°C,
and 5 min at 95°C, and then for 40 cycles of 5 s at 95°
C, and 1 min at 60°C. The thermal denaturation proto-
col was run at the end of the PCR to determine the
number of products that were present in the reactions.
All of the reactions were run in triplicate and included
non-template controls for each gene. The amount of
each gene was normalized to b-actin as the reference
gene. The real-time PCR primers for each gene were
designed using the Primer Express software, version 2.0
(Applied Biosystems), with a Tm of 60°C and a primer
length of between 18 nt and 25 nt. We used a standard
analysis to calculate the amplification of the erbB2 genes
by the 2^-DCt method as described previously [30]. The
real-time PCR was performed twice for each sample,
and we used the mean value of these two independently
data points.
Calibration curves
For each assay, we prepared a reference calibration
curve as described previously, [31] which containing a
nine-concentration titration series representing the
erbB2 and b-actin genes at 10-fold dilutions from 1.0
ng/μlt o1 . 0×1 0
-8 ng/μl (see Additional file 2: Supple-
mental Figure S1). Each calibration curve was produced
in triplicate. We tested the reproducibility of the calibra-
tion curves for erbB2 and b-actin genes determination
according to the slopes and the correlation coefficients
of the experimental fittings of the calibration curves
from each experiment. The mean slopes of the calibra-
tion curves for the two genes were similar: -3.285 for
erbB2 and -3.036 for b-actin. The mean correlation
coefficients of the curve fitting were 0.989 and 0.994,
respectively. We here, showed three representative
slopes for b-actin and erbB2 with the standard errors:
slopes b-actin: -3.122; -2.772; -3.215, standard deviation
is 0.234 and standard error is 0.135; slopes erbB2:
-3,263; -3,232; -3,360, standard deviation is 0,066 and
standard error 0.039. A slope of -3.3 +/- 10% reflects an
efficiency of 100% +/- 10% of the PCR reaction [32]. For
this reason, the slopes for the two genes are similar (p
values = 0,150). We calculates these gene CN of the
patients using the Ct values of the vector and calculating
the CN vector according to the formula [31,33,34]:
Number of copies =(amount(ng) ∗ 6.022 × 1023)/
(length(bp) ∗ 1.0 × 109 ∗ 650).
This formula takes into account 6.022 × 10
23 (mole-
cules/mole) that is the Avogadro’sn u m b e ra n d6 6 0D a
t h a ti st h ea v e r a g ew e i g h to fas i n g l eb a s ep a i r .T h e
non-integer results were treated on the basis of the cut-
off CN >2 and CN ≤2 and they were rounded off, parti-
c u l a r l y ,t h ev a l u e sw e r er o u n d e dd o w ni ft h ed e c i m a l
value was between 0 and 4; while they were rounded up
if the decimal value was between 5 and 9.
The primers for the erbB2 gene were:
erbB2 F: TATGCAGGGCTGACGTAGTGC
erbB2 R: AATGTGTGCCACGAAACTGCT
The primers for the b-actin gene were:
b-actin F: CCTCACCCTGAAGTACCCCA,
b-actin R: TCGTCCCAGTTGGTGACGAT.
Cell sorting of circulating tumor cells by flow cytometry
Whole peripheral blood samples from six EC patients
were centrifuged at 2850 × g for 10 min at 4°C, and the
plasma was removed. The resulting cell pellet was sus-
pended by dilution with phosphate-buffered saline (PBS)
and then centrifuged at 1700 × g for 30 min at 4°C, to
separate mononuclear cells. Then, the mononuclear
cells were stained at 4°C and avoiding light exposure,
with: cytokeratins CK8-, CK18-, and CK19-FITC (mono-
clonal antibody A45-B/B3; Micromet, Munich, Ger-
many) 1:30; CD326-APC (EpCAM, Becton Dickinson)
1:10; and CD45-PerCP (Becton Dickinson) 1:10. The
samples were then washed with 2 ml PBS with 2% fetal
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C. The supernatant was removed and the cell pellets
were suspended as before (2 ml PBS with 2% fetal
bovine serum), and filtered with 30 μm filcons (Becton
Dickinson) before analysis by flow cytometry. The flow
cytometry gating strategies included: a first gate based
on physical parameters forward scatter (FSC) versus side
scatter (SSC), to eliminate cell debris and dead cells.
The leukocyte population was excluded with a second
gate in the CD45 versus SSC dot plot. The CTCs were
selected by a gate based on cytokeratin CK8, CK18 and
CK19/CD326-positive cells. These cells were purified by
cell sorting with a BD FACS Aria instrument, and col-
lected in a 2 ml tube.
Immunohistochemistry
One or two representative tumor blocks from each patient
were examined by immunohistochemistry. We analyzed
erbB2 for 14 EC tissue samples with an anti-erbB2 anti-
body (1:500; DakoCytomation). The unmasking was per-
formed in 10 mM citrate buffer, pH 6, for 45 min at 97°C.
Blocking was performed with BSA 2,5%, normal goat
serum 0.05%, PBS 1%, Tween 0,5% for 1 h at room tem-
perature. The signal was revealed according to DAKO kits,
for 15 min (each, for biotin and streptavidin), at room
temperature. DAB was from DakoCytomation, and the
slides were mounted and examined under a Leica DC500
compound microscope (Nussloch, Germany).
ErbB2 immunohistochemical staining in EC samples
was scored according to Kuwabara et al.,[ 3 5 ] ,w h o
adopted the same criteria previously validated for breast
cancer; namely: no staining or weak staining in fewer
than 10% of the tumor cells (-); weak staining in part of
the membrane in more than 10% of the tumor cells (+);
complete staining in part of the membrane with weak
or moderate intensity in more than 10% of the tumor
cells, (++); strong staining in more than 10% of the
tumor cells, (+++).
VEGF ELISA assay
The levels of the VEGF protein in the plasma used for
erbB2 amplifications from 41 EC patients were deter-
mined using a commercially available sandwich enzyme
immunoassay kit (Endogen VEGF ELISA kit, Cambridge,
USA). All sample were assayed in duplicate.
Statistical analysis
All of the data are presented as medians ± standard
error. Statistical significance was calculated using the
Mann-Whitney test. Raw real-time PCR data for erbB2
amplification in the plasma from healthy controls and
patients with EC were normalized using the b-actin
amplification values. The erbB2 CN values were divided
into two groups, as “CN ≥2” and “CN <2”. Potential
associations between clinicopathological variables and
erbB2 CN were analyzed by Pearson’s Chi-Squared.
Kaplan-Meier survival curves were constructed for
erbB2 and VEGF low and high level groups, as well as
for the clinicophathological variables available in our
dataset. Differences in survival between the groups were
tested for statistical significance by log-rank tests. Pro-
gression free survival time was measured from the date
of registration in the study to the date of progression or
last follow-up visit. The patients derived all from one
clinic and were all of Caucasian origin. P <0 . 0 5w a s
considered as statistically significant.
Receiver operating characteristic (ROC) curves and the
area under the ROC curves were generated to calculate
the specificity and sensitivity of erbB2 CN variation in
the healthy controls and the EC patients.
Results
Detection of erbB2 copy number variations in DNA from
plasma of patients with esophageal carcinoma
Real-time PCR with CN analysis was used for the analy-
sis of DNA from the plasma of 41 patients with EC,
before their surgical resection and chemotherapy treat-
ment. Here, we also analyzed the CN variations for
erbB2 in 34 healthy controls. As shown in Figure 1A,
the erbB2 CNs were significantly higher in the plasma
samples from the 41 EC patients, with respect to the 34
healthy control subjects (P = 0.001). In particular, 24 EC
patients had CN ≤2 (58.5%), while 17 EC patients had
CN >2 (41.4%) with a median CN of 2 and a standard
deviation of 5.02. The 34 healthy control subjects
showed a median of erbB2 CN of 1, with a standard
deviation of 0.16. The representative calibration curves
for the erbB2 and b-actin genes used for the CN varia-
tion analysis are shown in the Additional file 2: Supple-
mental figure S1 (Figure S1).
We also evaluated the CN data of erbB2 by real-time
PCR using the ROC curves, which provide an analysis of
the sensitivity and specificity of the assay. The ROC
curves were constructed for the erbB2 CN in plasma,
examining the 41 EC patients and 34 healthy controls.
As shown in Figure 1B, in this sample set, erbB2 had an
area under the curve (AUC) of 0.95, and differed signifi-
cantly from that of a chance result (AUC: 0.5) (P =1 . 3 9
×1 0
-11). For distinguishing patients with EC from
healthy controls, erbB2 had an 80% sensibility, and a
95% specificity (Figure 1B).
The association of the erbB2 CN variations with the
clinicopathological characteristics of the EC patients are
summarized in the Additional file 1: Supplemental table
S1. The association of erbB2 CN and the clinical fea-
tures of the esophageal carcinoma were also assessed by
the Chi-Squared Test. There were no significant statisti-
cal direct correlations between erbB2 CN and these
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ciated with erbB2 CN >2 (P = 0.05). Despite the small
number of patients, our dataset comprises all the char-
acteristic of the tumor as regard T stage, N status,
tumor grading, tumor location and histology, see Addi-
tional file 1: Supplemental table S1 (tab.S1). All CT
values of real time PCR assay for EC patients and
healthy controls subjects were showed in the Additional
file 3: Supplemental table S2 (tab.S2).
ErbB2 copy number variations predict survival rates in
esophageal carcinoma patients
We used Kaplan-Meier analyses to look for correlations
between the erbB2 CN variations and EC patient pro-
gression-free survival. The survival curves for the EC
patients were divided according to erbB2 CN ≤2a n d
erbB2 CN >2, as illustrated in Figure 2 on the basis of
CN median of EC patients. We also tried to divide the
patients into lose (CN <1), normal (2 ≥ CN ≥1) and
gain (CN ≥ 2) of erbB2, 6, 14 and 21 patients respec-
tively, and by using Kaplan-Meier analyses we did not
reach a statistical significance but we saw the same ten-
dency as for the survival analysis with cut-off 2 (Addi-
tional file 2: Supplemental Figure S1 C). The number of
patients here analyzed is too small to be divided into
t h r e eg r o u p s ,f o rt h i sr e a s o nw ea n a l y z e da l lt h ed a t a
with the CN cut-off value of 2. ErbB2 CN >2 was signif-
icantly negatively correlated to the survival rates of
these EC patients (P = 0.03; Figure 2A).
In further analyses according to the tumor grading,
the EC patients with a tumor grading G2 can be further
stratified according to erbB2 CN ≤2a n derbB2 CN >2,
which were again significantly negatively correlated to
the survival rates of these EC patients (P = 0.03; Figure
2B). These analyses for the EC patients with tumor
gradings G1 and G3 did not show any statistically signif-
icant effects on their survival rates due to the small
n u m b e r so fp a t i e n t si nt h e s es u b g r o u p s( d a t an o t
shown).
Our dataset also showed an heterogeneous histological
composition when stratified accordingly to the histotype.
Here, erbB2 CN variations were significantly correlated
t ot h es u r v i v a lr a t e so ft h ea d e n o c a r c i n o m ac a s e s( P =
0.03; Figure 2C). Similarly, we analyzed the correlations
between the N status and survival rates: erbB2 CN >2 in
the N1 subgroup was significantly negatively correlated
to the survival rates of these EC patients (P =0 . 0 5 ,
Figure 2D). Again, these analysis for the EC patients with
Figure 1 ErbB2 copy number variations in DNA in plasma from patients with esophageal carcinoma versus healthy controls and
relative ROC curve analysis of the assay.( A) Box plot showing the ranges of erbB2 CN in DNA from the plasma of patients with EC (n.41)
with respect to healthy controls (n.34).
*P = 0.001. Horizontal bars in the box represent the medians of CN which is equal to 2 for patients and 1 for controls. (B) Receiver operating
characteristic (ROC) curves (solid line; AUC, 0.95) were generated to compare healthy controls with EC patients for erbB2 with the null hypothesis
(dashed line; AUC, 0.5; P = 1.39 × 10
-11). The assay showed 80% sensibility and 95% specificity. Data are representative of three independent
experiments.
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nificance for the survival rates due to the small numbers
of patients in these subgroups (data not shown).
Correlations of erbB2 copy number variations with VEGF
plasma levels
We then tested erbB2 CN for possible associations with
VEGF protein levels in the plasma from the same EC
patients (Figure 3). The VEGF levels data were available
in our tissue/serum databank collection, and have been
previously published [36]. The erbB2 CN variations did
not show any significant direct associations with VEGF
levels in the plasma (Figure 4A). However, when the EC
patients were stratified into the low and high VEGF
groups, as shown in Figure 4B, high VEGF levels in the
plasma of those EC patients were significantly negatively
correlated to their survival rates (P < 0.00001). In a
further Kaplan-Meier analysis, we also looked at the
influence of erbB2 CN variations in these EC patients
with low and high VEGF levels: an erbB2 CN >2 was
Figure 2 Kaplan-Meier survival curves for erbB2 copy number variations in plasma from patients with esophageal carcinoma
according to clinical characteristics.( A) All patients with EC; (B) EC patients with tumor grading G2; (C) EC patients with adenocarcinoma
histology; (D) EC patients with N1 stage disease. The patients are divided according to erbB2 CN ≤2 (solid line) and erbB2 CN >2 (dashed line)
subgroups. Data are representative of three independent experiments.
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the EC patients with low VEGF expression (P = 0.05;
Figure 3C). Altogether, these results show that erbB2
CN >2 status and low VEGF levels in the plasma of
these EC patients appear to be useful to stratify a sub-
group of patients with worse survival rates.
Isolation of circulating tumor cells from peripheral blood
of esophageal carcinoma patients
To answer the question of whether this DNA in the
plasma of these EC patients was derived from CTCs, we
isolated these cells from these patients. Indeed, we
detected CTCs that were disseminated in the peripheral
Figure 3 ErbB2 copy number variations in plasma from patients with esophageal carcinoma according to VEGF plasma levels.( A)
Histogram showing lack of significant correlation between erbB2 CN variations and VEGF plasma levels in all patients with EC (n. 41), as
indicated. The numbers in the bars show the EC patients in each sub-group. (B, C). Kaplan-Meier survival curves for all patients with EC
according to low and high plasma levels of VEGF (B), and for patients with EC and low plasma levels of VEGF according to erbB2 CN ≤2 (solid
blu line) and erbB2 CN >2 (dashed green line). Data are representative of three independent experiments.
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isolated from the peripheral blood of these EC patients
by sorting the cells negatively for CD45 (a specific anti-
gen for lymphocytes) and by a gate based on epithelial
cytoskeleton components: the cytokeratins CK8, CK18
and CK19, and CD326 (EpCAM) (see Methods). Both,
the cytokeratins (CK8, CK18 and CK19) and the antigen
EpCAM have been used to identified epithelial cell
adhesion molecules, as previously used by Stoecklein et
al. as markers to isolate CTCs from lymph nodes and
bone marrow of patients with EC [11]. As previously
described, [37] we used the MDA-231T breast cell line
a st h ep o s i t i v ec o n t r o l( F i g u r e4 A ) .H e r ew es h o wt h a t
we were only able to successfully isolated positive cells
Figure 4 Isolation of CTCs using fluorescence-activated cell sorting.( A, B) Scatter plots for gating of cells positive to CK8, CK18, CK19 and
EpCAM in the MDA-231T breast cancer cell line (A; positive control) and from the blood of a representative patient with EC (B). (C) Histogram
showing erbB2 CN variations from sorting CTCs of patients with EC compared to the CN of DNA from plasma of the same patients. Data are
representative of three independent experiments.
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0.05%-0.1% of the 2.0 × 10
6 cells analyzed; Figure 4B),
from which we prepared genomic DNA for the determi-
nation of erbB2 C N .T h i sa n a l y s i sw a sp e r f o r m e di na l l
of the other five samples analyzed, with similar results
(data not shown). The peripheral blood of the healthy
controls was analyzed in the same way, but did not
show any cell population positive for CK8, CK18 and
CK19 and EpCAM, and negative for CD45 (data not
shown). The analyses of this DNA extracted from these
CTCs of the EC patients showed that the erbB2 CN was
in the same range (CN >2) as for the DNA isolated
from the plasma of the same (six) EC patients (Figure
4C). The comparison between the CN values from
plasma and from CTCs was showed in Additional file 4:
Supplemental table S3 (tab.S3).
ErbB2 protein expression in tumor tissue
We additionally performed immunohistochemistry ana-
lysis for erbB2 protein staining (in parallel sections) in
13 esophageal primary tumor tissue samples, four of the
tissues of which were included in the plasma DNA data-
set previously analyzed. Some tissue staining examples
are shown in the Additional file 5: Supplemental Figure
S2. Strong expression of erbB2 was showed for the case
code 1 patient (score +++), with intermediate expression
of erbB2 for the case code 2 patient (score ++) and low
expression for the case code 3 patient (score +) (the
Additional file 5: Supplemental Figure S2A). Control
experiments showed weak staining of erbB2 in prolifera-
tive epithelial tissues of healthy esophageal mucosa
(Additional file 5: Supplemental Figure S2 B).
Discussion
In clinical practice, the diagnosis and the staging of EC
is mainly based on the use of morphological and func-
tional clinical examinations. To date, serum-specific EC
markers do not exist, which is in contrast with the situa-
tion for other tumors of the gastrointestinal tract. Exam-
ples here, can be seen for gastric cancer, where Ca.19.9
has important role in diagnosis. At this time, we can
conclude that already identified single biomarkers show
a lack of sufficient sensitivity and specificity in EC, and
that it is likely that multiple markers will be needed
simultaneously to address the diagnosis and prognosis
of EC [3].
The relationship between erbB2 over-expression and
responses to treatment has not yet been established for
EC. New perspectives have been emerging, such as for
instance from the TOGA trial, that showed efficacy
results from a phase III study of trastuzumab (Hercep-
tin
®), a monoclonal antibody against erbB2: when given
with chemotherapy, survival benefits were seen for
patients with erbB2-positive early and metastatic gastric
cancer [9]. Thus, the data in this TOGA trial showed that
trastuzumab with chemotherapy is superior to che-
motherapy alone, with median overall survival signifi-
cantly improved with trastuzumab compared to
chemotherapy alone: 13.5 versus 11.1 months, respec-
tively. Trastuzumab is therefore a new and well-tolerated
treatment for erbB2-positive gastrointestinal cancer [38].
VEGF is an additional marker, which is over-expressed
in about 30% to 60% of esophageal tumors. High serum
levels of VEGF correlate with advanced stages and poor
overall survival in patients that receive curative surgery
[39]. Several studies have shown that VEGF-C over-
expression correlates with depth of tumor invasion, lym-
phatic invasion and lymph node metastasis.
CTCs and free DNA in plasma have been analyzed in
many tumors, such as breast, colorectal, lung and renal
carcinomas. These have been shown to be crucial links
between primary cancers and those that reach a meta-
static stage, which represent the leading cause of death
for most malignancies [40-46]. Our study has evaluated
the evolving model of detection of tumor marker CN in
DNA from plasma of EC patients. We have here identi-
fied erbB2 CN variations in the cell-free DNA of 41
patients with EC in comparison with 34 healthy con-
trols. Our results are in agreement with the study of
Chiang PW. et al.,t h a ts h o w e derbB2 amplification in
39 plasma from esophageal carcinoma patients with
only adenocarcinoma histotype. The system of detection
of erbB2 in DNA from plasma by real-time PCR is inno-
vative and with the validation in a larger cohort of
patients can be used for monitoring the assessment of
the extent of tumor dissemination and the potential
development of distant metastasis. This method uses an
easier and not invasive peripheral blood sample in
respect with the FISH assay (PathVysion FISH assay)
performed on tumor biopsies actually approved by the
US Food and Drug Administration (FDA) for determin-
ing the eligibility for Herceptin clinical treatment in
breast carcinoma with erbB2 amplification.
We have further analyzed the erbB2 CN from CTCs
isolated from patients with EC and we have demonstrate
that it is similar to the DNA isolated from the plasma of
the same patients. These data indicate that in the
healthy controls, the DNA that we extracted was derived
from blood cells (mainly lymphocytes and granulocytes);
instead, in the EC patients, the free DNA in the plasma
is mainly derived from CTCs (see Additional file 6: Sup-
plemental Table S4, for estimation of the DNA content
in plasma). At this time, a question remains over the
origin of these CTCs: Are those cells derived from pri-
mary tumors or from cells that will create a metastases
foci? We cannot at present exclude that this DNA
derived from the primary tumor cells because of our
lack of DNA from the primary tumors in this study.
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this cohort analysis, is in agreement with another study
that has shown erbB2 amplification in CTCs isolated
from lymph nodes and bone marrow in 50% of EC
patients [11]. This study demonstrated that the rate of
erbB2 amplification is higher in CTCs than in the pri-
mary tumors, where the rates of amplification were esti-
mated at about 10% [10,47]. These data are in
agreement with the observation that erbB2 CN varia-
tions are a later phenomenon in EC that is mainly asso-
ciated with the circulating tumor cells. Our data
additionally demonstrate that the CTCs isolated from
the peripheral blood of these EC patients have a similar
type of erbB2 amplification to that seen by Stoecklein et
al. in CTCs isolated from bone marrow and lymph
nodes [11]. The present study underlines that the detec-
tion of cell-free DNA from plasma through the taking of
a non-invasive blood sample can provide relevant infor-
mation on the disease status of patients with EC. It is
important to underline that despite the small number of
EC patients (n.41) included in our cohort, the incidence
of this tumor is of 2195 cases for year in Italy with 40
cases in Naples and a raw rate (number of cases per one
hundred thousand of inhabitants for year) of 2 in south-
ern Italy (data from Italian Association tumors register
AIRTUM 2000-2003; see: http://www.registri-tumori.it/
cms/). Furthermore, our dataset is heterogeneous for
composition resembling all the clinical characteristics of
the esophageal carcinoma.
We have shown here a correlation between erbB2 CN
from plasma and progression-free survival in patients
with EC with 70 months (5,8 years) of follow-up. The
EC patients were divided into two subgroup on the
basis of CN median (cut-off CN = 2), other separation
in subgroups were made but they did not shown corre-
lation to progression-free survival for the small number
of patients here analyzed (see the Additional file 2: Sup-
plemental Figure S1 C). The EC patients with erbB2 CN
≤2 showed a better survival with respect to those with
CN >2 erbB2. These data demonstrate that the detection
of erbB2 CN in the plasma of EC patients can predict
the survival rates of patients before the use of clinical
resection strategies. These data emphasize the results
obtained by Mimura et al., that found an association
only between the survival rate and the erbB2 gene
amplification (7 positive patients versus 59 negative
patients) detected by fluorescence in situ hybridization
(FISH) method and not between the survival rate and
positive or negative erbB2 staining detected by immuno-
histochemistry assay [46]. Furthermore, Kuwabara et al.,
also demonstrated the correspondence between gene
amplification (analyzed by FISH) and protein expression
(analyzed by immunohistochemistry) of erbB2,
underlining that gene amplification is an indicator of
poor prognosis in esophageal carcinoma [35].
In particular, we found that an erbB2 CN >2 was cor-
related to a worst survival rate in the adenocarcinoma
histotype. Of note, esophageal adenocarcinoma has been
shown to have increased in western countries over the
last half century, and especially in European Caucasian
white men, although esophageal squamous cell carci-
noma remains the dominant type of EC in both western
and Asian countries [47-49]. The rapid increase of this
adenocarcinoma histotype has been attributed to an
increased prevalence of gastroesophageal reflux disease
and obesity [48-50].
Furthermore, our dataset confirms the importance of
N status evaluation through our Kaplan-Meier analysis.
When divided according to N status, an erbB2 CN >2
impaired survival rates of patients with an N1 status,
confirming the importance of the amplification of the
erbB2 gene in the prediction of a worse clinical
outcome.
We also confirmed the importance of the VEGF
expression in our dataset, demonstrating that high
VEGF expression impairs the survival rate of these EC
patients. Moreover, we have identified a new EC cate-
gory risk: low VEGF expression and erbB2 CN >2.
These data are of importance because of the potential
new therapies, anti-erbB2, that might be applied to EC
patients who will not derive any benefit from anti-VEGF
treatment.
Conclusion
The use of these methods to detect DNA in the plasma
of such EC patients should greatly benefit the “early
detection” phase before tumor resection and chemother-
apy, and should enhance the importance for changes in
therapies for those low VEGF-positive EC patients. The
validation of the erbB2 detection in a large scale popula-
tion thus represents a new prognostic marker that can
be used as a sign of EC early warning, and for the pre-
diction of the disease progression. Thus, inhibition of
erbB2 activity might represent a new avenue for success-
ful inhibition of potential metastasis formation, and
represents a new therapeutic target for future persona-
lized cancer therapies.
These data indicate the association between erbB2 CN
variations and progression-free survival in these patients
with EC. As previously said, the number of patients ana-
lyzed here is not sufficient to draw a conclusion on the
possible diagnostic application, although we know that
our tumors dataset represents a well morphological dis-
tribution in the Caucasian population affected by eso-
phageal cancer. At this time, a large study that can be
designed to include both EC and other tumors of the
Andolfo et al. BMC Cancer 2011, 11:126
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Page 10 of 12gastrointestinal tract, thus will definitively enhancing our
methodology and findings.
Additional material
Additional file 1: Supplemental Table S1: Association of erbB2 copy
number variations with the clinicopathological features of the
patients with esophageal carcinoma.
Additional file 2: Supplemental Figure S1: Calibration curve for
erbB2 and b-actin genes relating cycle threshold to gene copy
number.( A) For the erbB2 gene CN. Top right, equation of the curve
and the relative mean correlation coefficient (R2). (B) For the b-actin
gene CN. Top right, as for (A). (C) Kaplan-Meier survival curves for all
patients with EC according to lose, normal and gain erbB2 CN.
Additional file 3: Supplemental Table S2: CT values of real time PCR
of erbB2 and b-actin genes for all patients and controls.
Additional File 4: Supplemental Table S3: Copy number variation of
CTCs from EC patients compared to copy number variation of DNA
from plasma of the same patients.
Additional File 5: Supplemental Figure S2: ErbB2 in esophageal
tumor tissues.( A) Patterns of ErbB2 staining with a polyclonal antibody
in EC tumor tissues 1, 2 and 3, showing scores of +++, ++ and +,
respectively. (B) ErbB2 staining as for (A), in healthy esophageal mucosa
(CTR).
Additional File 6: Supplemental Table S4: Quantization of DNA
extracted from plasma of patients and controls.
Abbreviations
EC: esophageal carcinoma; CN: copy number variations; CTCs: circulating
tumor cells.
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